CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands |
Cumulative Effect, Period of Adoption, Adjustment
Legacy Convertible Preferred Stock
|
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
|
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid-In Capital
|
Cumulative Effect, Period of Adoption, Adjustment |
Cumulative Effect, Period of Adoption, Adjusted Balance
Common Stock
|
Cumulative Effect, Period of Adoption, Adjusted Balance
Additional Paid-In Capital
|
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Deficit
|
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Other Comprehensive (Loss) Income
|
Cumulative Effect, Period of Adoption, Adjusted Balance
Notes Receivable
|
Cumulative Effect, Period of Adoption, Adjusted Balance |
Legacy Convertible Preferred Stock |
Series E Preferred Stock
Common Stock
|
Series E Preferred Stock
Additional Paid-In Capital
|
Series E Preferred Stock |
Series E1 Preferred Stock
Common Stock
|
Series E1 Preferred Stock
Additional Paid-In Capital
|
Series E1 Preferred Stock |
Common Stock
In-process research and development
|
Common Stock |
Additional Paid-In Capital
In-process research and development
|
Additional Paid-In Capital |
Accumulated Deficit |
Accumulated Other Comprehensive (Loss) Income |
Notes Receivable |
In-process research and development |
Total |
BALANCE at Dec. 31, 2018 |
$ (276,889)
|
|
|
|
|
|
|
|
|
|
$ 276,889
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE (in shares) at Dec. 31, 2018 |
(84,092,669)
|
|
|
|
|
|
|
|
|
|
84,092,669
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE at Dec. 31, 2019 |
$ (436,533)
|
|
|
|
|
|
|
|
|
|
$ 436,533
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE (in shares) at Dec. 31, 2019 |
(100,038,109)
|
|
|
|
|
|
|
|
|
|
100,038,109
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Preferred Stock (in shares) |
|
|
|
|
|
|
|
|
|
|
|
16,426,267
|
|
|
3,046,623
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
$ 2
|
$ 134,665
|
$ 134,667
|
|
$ 24,977
|
$ 24,977
|
|
|
|
|
|
|
|
|
|
BALANCE at Dec. 31, 2018 |
|
$ 11
|
$ 276,878
|
$ 276,889
|
$ 13
|
$ 283,318
|
$ (190,666)
|
$ (96)
|
$ (249)
|
$ 92,320
|
|
|
|
|
|
|
|
|
$ 2
|
|
$ 6,440
|
$ (190,666)
|
$ (96)
|
$ (249)
|
|
$ (184,569)
|
BALANCE (in shares) at Dec. 31, 2018 |
|
106,977,440
|
|
|
126,329,695
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,352,255
|
|
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of Common Stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
708
|
|
|
|
|
708
|
Exercise of Common Stock options (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,217,255
|
|
|
|
|
|
|
|
Vesting of restricted Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
|
7
|
|
|
|
|
8
|
Vesting of restricted Common Stock (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,904,182
|
|
|
|
|
|
|
|
Issuance of Common Stock for acquisitions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,563
|
|
|
|
|
3,563
|
Issuance of Common Stock for acquisitions (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,066,373
|
|
|
|
|
|
|
|
Issuance of common stock for acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,563
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,215
|
|
|
|
|
5,215
|
Common Stock warrants issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,038
|
|
|
|
|
1,038
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(103,596)
|
|
|
|
(103,596)
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171
|
|
|
171
|
BALANCE at Dec. 31, 2019 |
|
$ 13
|
436,520
|
436,533
|
$ 16
|
453,242
|
(294,262)
|
75
|
|
159,071
|
|
|
|
|
|
|
|
|
$ 3
|
|
16,722
|
(294,262)
|
75
|
|
|
(277,462)
|
BALANCE (in shares) at Dec. 31, 2019 |
|
128,100,821
|
|
|
154,913,934
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,813,113
|
|
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayment of notes receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(249)
|
|
|
$ 249
|
|
|
Repayment of notes receivable (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(76,461)
|
|
|
|
|
|
|
|
Exercise of Common Stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
136
|
|
|
|
|
136
|
Exercise of Common Stock options (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
314,809
|
|
|
|
|
|
|
|
Vesting of restricted Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
|
|
|
4
|
Vesting of restricted stock units (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,500,915
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,333
|
|
|
|
|
2,333
|
Common Stock warrants issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
211
|
|
|
|
|
211
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(45,570)
|
|
|
|
(45,570)
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(27)
|
|
|
(27)
|
BALANCE at Jun. 30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 16
|
|
455,926
|
(339,832)
|
48
|
|
|
$ 116,158
|
BALANCE (in shares) at Jun. 30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
158,729,658
|
|
|
|
|
|
|
|
BALANCE at Dec. 31, 2019 |
$ (436,533)
|
|
|
|
|
|
|
|
|
|
$ 436,533
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE (in shares) at Dec. 31, 2019 |
(100,038,109)
|
|
|
|
|
|
|
|
|
|
100,038,109
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE (in shares) at Dec. 31, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,038,109
|
BALANCE at Dec. 31, 2019 |
|
$ 13
|
436,520
|
436,533
|
$ 16
|
453,242
|
(294,262)
|
75
|
|
159,071
|
|
|
|
|
|
|
|
|
$ 3
|
|
16,722
|
(294,262)
|
75
|
|
|
$ (277,462)
|
BALANCE (in shares) at Dec. 31, 2019 |
|
128,100,821
|
|
|
154,913,934
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,813,113
|
|
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of Common Stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
325
|
|
|
|
|
325
|
Exercise of Common Stock options (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
521,925
|
|
|
|
|
|
|
|
Vesting of restricted Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
|
6
|
|
|
|
|
7
|
Vesting of restricted Common Stock (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,307,357
|
|
|
|
|
|
|
|
Repurchase of shares for employee tax withholdings (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9,308)
|
|
|
|
|
|
|
|
Issuance of Common Stock for acquisitions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500
|
|
|
|
|
500
|
Issuance of Common Stock for acquisitions (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
61,060
|
|
|
|
|
|
|
|
Issuance of common stock for acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,006
|
|
|
|
|
8,006
|
Common Stock warrants issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,915
|
|
|
|
|
1,915
|
Common Stock warrants issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692,366
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(34,015)
|
|
|
|
(34,015)
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(84)
|
|
|
(84)
|
BALANCE at Dec. 31, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 23
|
|
844,188
|
(328,277)
|
(9)
|
|
|
515,925
|
BALANCE (in shares) at Dec. 31, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
224,626,597
|
|
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reverse recapitalization, net of transaction costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6
|
|
380,295
|
|
|
|
|
380,301
|
Reverse recapitalization, net of transaction costs (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63,139,263
|
|
|
|
|
|
|
|
BALANCE at Mar. 31, 2020 |
$ (436,533)
|
|
|
|
|
|
|
|
|
|
$ 436,533
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE (in shares) at Mar. 31, 2020 |
(100,038,109)
|
|
|
|
|
|
|
|
|
|
100,038,109
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE at Mar. 31, 2020 |
|
$ 13
|
$ 438,037
|
$ 438,050
|
$ 16
|
$ 454,759
|
$ (316,066)
|
$ (84)
|
|
$ 138,625
|
|
|
|
|
|
|
|
|
$ 3
|
|
16,722
|
(316,066)
|
(84)
|
|
|
(299,425)
|
BALANCE (in shares) at Mar. 31, 2020 |
|
130,138,012
|
|
|
156,951,125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,813,113
|
|
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of Common Stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
|
|
|
4
|
Exercise of Common Stock options (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,173
|
|
|
|
|
|
|
|
Vesting of restricted Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
2
|
Vesting of restricted Common Stock (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,750,360
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,074
|
|
|
|
|
1,074
|
Common Stock warrants issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
87
|
|
|
|
|
87
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(23,766)
|
|
|
|
(23,766)
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
132
|
|
|
132
|
BALANCE at Jun. 30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 16
|
|
455,926
|
(339,832)
|
48
|
|
|
$ 116,158
|
BALANCE (in shares) at Jun. 30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
158,729,658
|
|
|
|
|
|
|
|
BALANCE (in shares) at Dec. 31, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,038,109
|
BALANCE at Dec. 31, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 23
|
|
844,188
|
(328,277)
|
(9)
|
|
|
$ 515,925
|
BALANCE (in shares) at Dec. 31, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
224,626,597
|
|
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of Common Stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,665
|
|
|
|
|
3,665
|
Exercise of Common Stock options (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,846,734
|
|
|
|
|
|
|
|
Vesting of restricted Common Stock (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
112,030
|
|
|
|
|
|
|
|
Vesting of restricted stock units (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43,921
|
|
|
|
|
|
|
|
Repurchase of shares for employee tax withholdings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(145)
|
|
|
|
|
(145)
|
Repurchase of shares for employee tax withholdings (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9,172)
|
|
|
|
|
|
|
|
Issuance of Common Stock for acquisitions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
|
208,988
|
|
|
|
|
208,989
|
Issuance of Common Stock for acquisitions (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,049,338
|
|
|
|
|
|
|
|
Issuance of common stock for acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,300
|
|
|
|
|
$ 4,300
|
|
Issuance of common stock for acquired in-process research and development (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
334,370
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,216
|
|
|
|
|
6,216
|
Vesting of Trine Founder shares (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,850,938
|
|
|
|
|
|
|
|
Exercise of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2
|
|
320,567
|
|
|
|
|
320,569
|
Exercise of warrants (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,690,975
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(102,288)
|
|
|
|
(102,288)
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
113
|
|
|
113
|
BALANCE at Jun. 30, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 26
|
|
1,387,779
|
(430,565)
|
104
|
|
|
957,344
|
BALANCE (in shares) at Jun. 30, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
259,545,731
|
|
|
|
|
|
|
|
BALANCE at Mar. 31, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 25
|
|
1,326,945
|
(387,385)
|
(21)
|
|
|
939,564
|
BALANCE (in shares) at Mar. 31, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
252,436,919
|
|
|
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of Common Stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,485
|
|
|
|
|
3,485
|
Exercise of Common Stock options (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,683,506
|
|
|
|
|
|
|
|
Vesting of restricted Common Stock (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56,015
|
|
|
|
|
|
|
|
Vesting of restricted stock units (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,656
|
|
|
|
|
|
|
|
Repurchase of shares for employee tax withholdings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(91)
|
|
|
|
|
(91)
|
Repurchase of shares for employee tax withholdings (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,931)
|
|
|
|
|
|
|
|
Issuance of Common Stock for acquisitions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
|
49,141
|
|
|
|
|
49,142
|
Issuance of Common Stock for acquisitions (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,013,196
|
|
|
|
|
|
|
|
Issuance of common stock for acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,300
|
|
|
|
|
$ 4,300
|
|
Issuance of common stock for acquired in-process research and development (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
334,370
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,999
|
|
|
|
|
3,999
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(43,180)
|
|
|
|
(43,180)
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125
|
|
|
125
|
BALANCE at Jun. 30, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 26
|
|
$ 1,387,779
|
$ (430,565)
|
$ 104
|
|
|
$ 957,344
|
BALANCE (in shares) at Jun. 30, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
259,545,731
|
|
|
|
|
|
|
|